D Geho
- Courses1
- Reviews1
- School: George Mason University
- Campus:
- Department: Biology
- Email address: Join to see
- Phone: Join to see
-
Location:
4400 University Dr
Fairfax, VA - 22030 - Dates at George Mason University: October 2006 - October 2006
- Office Hours: Join to see
Biography
George Mason University - Biology
Head of Imaging at Vertex Pharmaceuticals
Pharmaceuticals
David
Geho
Cambridge, Massachusetts
Board-certified physician-scientist and experienced leader in Translational R&D
Experience
Case Western Reserve University School of Medicine
Adjunct Professor
D worked at Case Western Reserve University School of Medicine as a Adjunct Professor
Vertex Pharmaceuticals
Head of Translational Biology
D worked at Vertex Pharmaceuticals as a Head of Translational Biology
Vertex Pharmaceuticals
Head of Imaging
D worked at Vertex Pharmaceuticals as a Head of Imaging
Vertex Pharmaceuticals
Global Head of Clinical Biomarkers
D worked at Vertex Pharmaceuticals as a Global Head of Clinical Biomarkers
Merck
Director, Imaging
D worked at Merck as a Director, Imaging
Roche
Senior Leader, Translational Medicine-Oncology
D worked at Roche as a Senior Leader, Translational Medicine-Oncology
GE Healthcare
Clinical Project Leader
Clinical Development of Molecular Imaging Radiotracers
Education
Eastman School of Music
Bachelor of Music
French Horn Performance
Case Western Reserve University School of Medicine
MD and PH.D.
Case Western Reserve University School of Medicine
Adjunct Professor
National Cancer Institute
Medical Staff Fellow
Anatomic Pathology Residency
Smart hydrogel particles for biomarker harvesting
See application of this nanotechnology at Ceres Nanosciences (http://www.ceresnano.com)Method of isolating analytes from a sample
See application of this nanotechnology at Ceres Nanosciences (http://www.ceresnano.com)MRNA-BASED GENE EXPRESSION FOR PERSONALIZING PATIENT CANCER THERAPY WITH AN MDM2 ANTAGONIST
This biomarker invented to select patients for MDM2 inhibitor therapy is further described the the British Journal of Haematology (http://onlinelibrary.wiley.com/doi/10.1111/bjh.13411/abstract)Tissue preservation and fixation method
Novel fixative that enables molecular analyses of proteins while preserving morphological detail. Currently sold by Grace BioLabs as TheraLin Universal Tissue Fixative (http://www.gracebio.com/group/theralin/theralinr-universal-tissue-fixative.html)
Publications
Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study
The Lancet Oncology
Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study
The Lancet Oncology
Nanoparticles: potential biomarker harvesters
Current Opinion in Chemical Biology
Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study
The Lancet Oncology
Nanoparticles: potential biomarker harvesters
Current Opinion in Chemical Biology
RG7212 Anti-TWEAK mAb Inhibits Tumor Growth through Inhibition of Tumor Cell Proliferation and Survival Signaling and by Enhancing the Host Antitumor Immune Response.
Clinical Cancer Rearch
Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study
The Lancet Oncology
Nanoparticles: potential biomarker harvesters
Current Opinion in Chemical Biology
RG7212 Anti-TWEAK mAb Inhibits Tumor Growth through Inhibition of Tumor Cell Proliferation and Survival Signaling and by Enhancing the Host Antitumor Immune Response.
Clinical Cancer Rearch
Smart hydrogel particles: biomarker harvesting: one-step affinity purification, size exclusion, and protection against degradation.
Nano Letters
See application of this technology at Ceres Nanosciences (www.ceresnano.com)
Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study
The Lancet Oncology
Nanoparticles: potential biomarker harvesters
Current Opinion in Chemical Biology
RG7212 Anti-TWEAK mAb Inhibits Tumor Growth through Inhibition of Tumor Cell Proliferation and Survival Signaling and by Enhancing the Host Antitumor Immune Response.
Clinical Cancer Rearch
Smart hydrogel particles: biomarker harvesting: one-step affinity purification, size exclusion, and protection against degradation.
Nano Letters
See application of this technology at Ceres Nanosciences (www.ceresnano.com)
Exposure and Tumor Fn14 Expression as Determinants of Pharmacodynamics of the Anti-TWEAK Monoclonal Antibody RG7212 in Patients with Fn14-Positive Solid Tumors.
Clinical Cancer Research
Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study
The Lancet Oncology
Nanoparticles: potential biomarker harvesters
Current Opinion in Chemical Biology
RG7212 Anti-TWEAK mAb Inhibits Tumor Growth through Inhibition of Tumor Cell Proliferation and Survival Signaling and by Enhancing the Host Antitumor Immune Response.
Clinical Cancer Rearch
Smart hydrogel particles: biomarker harvesting: one-step affinity purification, size exclusion, and protection against degradation.
Nano Letters
See application of this technology at Ceres Nanosciences (www.ceresnano.com)
Exposure and Tumor Fn14 Expression as Determinants of Pharmacodynamics of the Anti-TWEAK Monoclonal Antibody RG7212 in Patients with Fn14-Positive Solid Tumors.
Clinical Cancer Research
MDM2 antagonist clinical response association with a gene expression signature in acute myeloid leukaemia.
British Journal of Haematology
